Keywords: genzyme, corp, rights, tgf-beta-2, granted, celtrix, pharmaceuticals

Genzyme Corp Rights to TGF-Beta-2 Granted

Article | 19 February 1998

Celtrix Pharmaceuticals has granted Genzyme Corp's Tissue RepairDivision global development and marketing rights to its recombinant TGF-beta-2 antibody, expanding their ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genzyme

Go to company listing

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing